Actinium-225 Radioligand Achieves PSA Declines in Advanced Prostate Cancer Trial
A first-in-human trial of actinium-225-PSMA-CY313 demonstrated manageable salivary toxicity alongside preliminary biochemical and radiographic responses in heavily pretreated metastatic castration-resistant ...

